The hardware and bandwidth for this mirror is donated by METANET, the Webhosting and Full Service-Cloud Provider.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]metanet.ch.

replicateBE: Average Bioequivalence with Expanding Limits (ABEL)

Performs comparative bioavailability calculations for Average Bioequivalence with Expanding Limits (ABEL). Implemented are 'Method A' / 'Method B' and the detection of outliers. If the design allows, assessment of the empiric Type I Error and iteratively adjusting alpha to control the consumer risk. Average Bioequivalence - optionally with a tighter (narrow therapeutic index drugs) or wider acceptance range (South Africa: Cmax) - is implemented as well.

Version: 1.1.3
Depends: R (≥ 3.5.0)
Imports: readxl (≥ 1.0.0), PowerTOST (≥ 1.5.3), lmerTest, nlme, pbkrtest, graphics, grDevices
Suggests: knitr, rmarkdown, testthat, devtools
Published: 2022-05-02
DOI: 10.32614/CRAN.package.replicateBE
Author: Helmut Schütz ORCID iD [aut, cre], Michael Tomashevskiy [ctb], Detlew Labes ORCID iD [ctb]
Maintainer: Helmut Schütz <helmut.schuetz at bebac.at>
BugReports: https://github.com/Helmut01/replicateBE/issues
License: GPL (≥ 3)
URL: https://github.com/Helmut01/replicateBE
NeedsCompilation: no
Materials: README NEWS
In views: ClinicalTrials
CRAN checks: replicateBE results

Documentation:

Reference manual: replicateBE.pdf
Vignettes: replicateBE

Downloads:

Package source: replicateBE_1.1.3.tar.gz
Windows binaries: r-devel: replicateBE_1.1.3.zip, r-release: replicateBE_1.1.3.zip, r-oldrel: replicateBE_1.1.3.zip
macOS binaries: r-release (arm64): replicateBE_1.1.3.tgz, r-oldrel (arm64): replicateBE_1.1.3.tgz, r-release (x86_64): replicateBE_1.1.3.tgz, r-oldrel (x86_64): replicateBE_1.1.3.tgz
Old sources: replicateBE archive

Linking:

Please use the canonical form https://CRAN.R-project.org/package=replicateBE to link to this page.

These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.